Next 10 |
Cardiff Oncology ( TROV ) (formerly Trovagene) inks an agreement with PoC Capital, LLC to fund the completion of its ongoing Phase 1b/2 clinical trial evaluating onvansertib, combined with Roche's Avastin (bevacizumab) and chemo regimen FOLFIRI, in patients with KRAS mutation-positive me...
TrovaGene (NASDAQ: TROV ): Q1 GAAP EPS of -$0.41. More news on: TrovaGene, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
Thinly traded nano cap Trovagene (NASDAQ: TROV ) jumps 48% premarket on robust volume in reaction to interim data from a Phase 1/2 clinical trial evaluating lead drug onvansertib, combined with chemo regimen FOLFIRI and Roche's Avastin (bevacizumab), for the second-line treat...
Broadwind Energy (NASDAQ: BWEN ) +60% . on $19M order . More news on: Broadwind Energy, Inc., TrovaGene, Inc., SmileDirectClub, Inc., Stocks on the move, , Read more ...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...
SAN DIEGO , April 22, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal, prostate and leukemia, today announced the el...
SAN DIEGO , April 8, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including colorectal, prostate ...
SAN DIEGO , April 1, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, announced today that its Phase 1b /2 clinical tri...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...